Iovance Biotherapeutics (IOVA) AI Stock Analysis

• Market Cap: $767.13M
• Dividend Yield: N/A
• Average Volume (3M): 11.36M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.11
• Revenue Growth: 636.99%
• EPS Growth: 27.10%
• Country: US
• Employees: 838
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 361,853,880
• 10 Day Avg. Volume: 10,305,404
• 30 Day Avg. Volume: 11,359,291
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: 1.36
• Enterprise Value/Gross Profit: 6.58
• Enterprise Value/Ebitda: -0.91
• 1Y Price Target: $10.67
• Price Target Upside: 428.22% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 46 Neutral
• Price Target: $2.50 ▲(23.76% Upside)

Iovance Biotherapeutics faces significant financial challenges, with weak profitability and cash flow issues being the most impactful factors. While the earnings call provided a positive outlook with strategic restructuring and revenue growth, the technical indicators and valuation metrics remain weak. The overall stock score reflects these mixed signals, with financial performance being the most significant concern.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong market demand and successful product adoption, which is crucial for long-term sustainability and expansion.

Strategic Restructuring

The restructuring plan aims to improve operational efficiency and profitability, enhancing the company's financial health and competitive position.

Manufacturing Improvements

Improved manufacturing efficiency reduces costs and enhances product reliability, supporting long-term operational success and customer satisfaction.

Negative Factors

Profitability Challenges

Persistent profitability issues can hinder reinvestment and growth, posing risks to financial stability and long-term viability.

Cash Flow Constraints

Negative cash flow limits the company's ability to fund operations and invest in growth opportunities, impacting future prospects.

European Regulatory Setback

The withdrawal from the EMA submission affects the company's European expansion plans, limiting potential market reach and revenue growth.

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

How the Company Makes Money

Iovance Biotherapeutics generates revenue primarily through the development and commercialization of its cell therapy products. The company may earn revenue from product sales once its therapies receive regulatory approval and enter the market. Additionally, Iovance may engage in strategic partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments upon achieving specific development goals, and royalties on future sales of the therapies developed under these agreements. These partnerships not only enhance Iovance's financial resources but also facilitate the advancement of its product candidates through clinical trials and regulatory processes. Research grants and funding from government or non-profit organizations may also contribute to the company's revenue streams, particularly during the development stages of its therapies.

Iovance Biotherapeutics Financial Statement Overview

Summary

Iovance Biotherapeutics is experiencing significant revenue growth, marking its first substantial revenue generation. However, the company remains unprofitable with a negative net income and negative cash flow, indicating operational and profitability challenges. The balance sheet shows a strong equity position with low leverage, but sustained losses could impact financial stability.

Income Statement

Iovance Biotherapeutics has shown substantial revenue growth with total revenue increasing significantly from $1.18 million in 2023 to $212.68 million in TTM (Trailing-Twelve-Months), marking its first substantial revenue generation. However, despite revenue growth, the company remains unprofitable with a negative net income of $375.36 million in TTM. The gross profit margin is 19.2% in TTM, reflecting that costs are still high relative to revenue. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies and high operating costs.

Balance Sheet

The balance sheet shows a relatively strong equity position, with a debt-to-equity ratio of 0.07, suggesting low leverage. Stockholders' equity stands at $767.87 million, indicating financial stability. However, the negative net income affects the return on equity, which remains negative. The equity ratio is 79.4%, reflecting a strong capital structure with substantial equity financing.

Cash Flow

The company has a negative operating cash flow of $334.39 million in TTM, demonstrating cash outflows from operations. Free cash flow also remains negative at $347.50 million, indicating challenges in generating cash from operations after capital expenditures. However, the firm successfully raised $340.40 million through financing activities, supporting its cash position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	241.52M	164.07M	1.19M	0.00	0.00	0.00
Gross Profit	49.75M	40.08M	-9.57M	-21.14M	-13.98M	-8.71M
EBITDA	-361.58M	-351.67M	-427.43M	-374.76M	-328.27M	-250.87M
Net Income	-389.92M	-372.18M	-444.04M	-395.89M	-342.25M	-259.58M
Balance Sheet
Total Assets	907.44M	910.43M	780.35M	663.98M	777.33M	768.46M
Cash, Cash Equivalents and Short-Term Investments	301.18M	323.78M	279.87M	471.85M	504.41M	629.44M
Total Debt	53.17M	58.26M	75.86M	85.45M	71.53M	51.66M
Total Liabilities	208.95M	200.02M	195.74M	164.34M	155.67M	111.96M
Stockholders Equity	698.49M	710.40M	584.61M	499.64M	621.66M	656.50M
Cash Flow
Free Cash Flow	-323.54M	-364.05M	-384.11M	-313.18M	-265.51M	-251.93M
Operating Cash Flow	-303.41M	-352.98M	-361.82M	-292.76M	-227.94M	-205.13M
Investing Cash Flow	4.58M	-96.41M	-155.24M	256.45M	132.00K	-317.85M
Financing Cash Flow	200.81M	390.66M	462.96M	190.15M	239.27M	576.42M

Iovance Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Negative. The current price of 2.02 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.48, and below the 200-day MA of 3.71, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 38.74 is Neutral, neither overbought nor oversold. The STOCH value of 14.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IOVA.

Iovance Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMLX	57 Neutral	1.48B	-5.53	-183.14%	―	-100.08%	-2.45%
VIR	49 Neutral	730.70M	-1.29	-58.07%	―	-75.91%	-12.11%
IMTX	48 Neutral	890.96M	-10.08	-15.91%	―	83.36%	22.27%
IOVA	46 Neutral	$767.13M	―	-53.16%	―	636.99%	27.10%
KALV	45 Neutral	653.27M	-3.02	―	―	―	-13.14%
NUVB	45 Neutral	1.11B	-4.79	―	―	900.35%	70.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Iovance Biotherapeutics Corporate Events

Iovance Biotherapeutics Updates Corporate Presentation

On August 29, 2025, Iovance Biotherapeutics updated its corporate presentation for use at healthcare conferences and with analysts and stockholders. The presentation highlights the company’s progress in TIL therapy, including the commercial launch of products like Amtagvi and Proleukin, and outlines ongoing clinical trials and regulatory submissions, which could impact its market positioning and stakeholder interests.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Amends Sale Agreement with Jefferies

On August 22, 2025, Iovance Biotherapeutics entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC for an at-the-market offering program. This agreement allows the company to issue and sell up to $350 million of its common stock, with Jefferies acting as the sales agent. The sale of shares will be conducted under a prospectus supplement to the company’s registration statement, and Jefferies will receive a commission of up to 3% on the gross sales proceeds. This strategic move could enhance Iovance’s financial flexibility and strengthen its market position.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Gains Health Canada Approval

On August 18, 2025, Iovance Biotherapeutics announced that its product Amtagvi® (lifileucel) received approval from Health Canada for use in advanced melanoma patients who have progressed after anti-PD-1 and targeted therapies. This approval marks Iovance’s first marketing authorization outside the U.S., based on the C-144-01 trial results, and signifies a strategic step in addressing unmet needs in solid tumor cancers, with plans to authorize a Canadian treatment center soon.

The most recent analyst rating on (IOVA) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.